Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery

ClinicalTrials.gov ID: NCT04564833

Public ClinicalTrials.gov record NCT04564833. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery (The START Study)

Study identification

NCT ID: NCT04564833
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Renibus Therapeutics, Inc.; Industry
Enrollment: 152 participants

Conditions and interventions

Conditions

Interventions

Low Dose RBT-1 Drug
High Dose RBT-1 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 3, 2021
Primary completion: Nov 8, 2022
Completion: Feb 2, 2023
Last update posted: Apr 14, 2024

2021 – 2023

United States locations

U.S. sites: 18
U.S. states: 12
U.S. cities: 18

Facility	City	State	ZIP	Site status
Heart Center Research, LLC	Huntsville	Alabama	35801	—
Keck Hospital of USC	Los Angeles	California	90033	—
Santa Barbara Cottage Hospital	Santa Barbara	California	93102	—
Stanford University Medical Center	Stanford	California	94305	—
Yale University School of Medicine	New Haven	Connecticut	06519	—
MedStar Health Research Institute, Inc.	Washington D.C.	District of Columbia	20010	—
University of Chicago Hospital Anesthesia and Critical Care	Chicago	Illinois	60637	—
Indiana University Health Southern Indiana	Bloomington	Indiana	47403	—
Lutheran Medical Group	Fort Wayne	Indiana	46804	—
Brigham and Women's Hospital	Boston	Massachusetts	02115	—
McLaren Greater Lansing	Lansing	Michigan	48910	—
MyMichigan Medical Center	Midland	Michigan	48670	—
Mayo Clinic Rochester	Rochester	Minnesota	55905	—
Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire	03756	—
New York Presbyterian-Queens	Flushing	New York	11355	—
Columbia University Irving Medical Center	New York	New York	10032	—
Rochester General Hospital Center for Clinical Research	Rochester	New York	14621	—
University of Texas Southwestern Medical Center	Dallas	Texas	75390	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04564833, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 14, 2024 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04564833 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →